Review top news and interview highlights from the week ending September 16, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
MT026 had an overall response rate of 83.3% in a first-in-human, investigator-initiated trial.
Improved functional activity compared to ROR-1-targeted CAR-T therapies without the 2 forms of reprogramming was demonstrated in preclinical studies.
The announcement comes after positive top-line results in the ongoing KarMMa-3 study.
A substantial benefit noted for EtranaDez and val-rox is that they are delivered as a single-dose.
Fang recently presented at the European Society for Medical Oncology (ESMO) 2022 Congress.